Detalhe da pesquisa
1.
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.
Cancer Immunol Immunother
; 72(6): 1603-1618, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36562826
2.
Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced Prostate Cancer.
Pathobiology
; 90(5): 312-321, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004506
3.
Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period.
Urol Int
; 106(11): 1158-1167, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477131
4.
Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells.
J Biol Chem
; 295(46): 15636-15649, 2020 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32883810
5.
Microenvironment-Derived FGF-2 Stimulates Renal Cell Carcinoma Cell Proliferation through Modulation of p27Kip1: Implications for Spatial Niche Formation and Functional Intratumoral Heterogeneity.
Pathobiology
; 87(2): 114-124, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32229735
6.
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Cancer Immunol Immunother
; 68(10): 1621-1633, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31549213
7.
APOBEC3A Expression in Penile Squamous Cell Carcinoma.
Pathobiology
; 85(3): 169-178, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29166639
8.
PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept Study.
Diagnostics (Basel)
; 14(7)2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38611655
9.
Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment.
J Pathol
; 227(3): 325-35, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22262369
10.
Long-Term Survival of Patients with Stage T1N0M1 Renal Cell Carcinoma.
Cancers (Basel)
; 15(24)2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38136261
11.
Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma.
Cancers (Basel)
; 15(20)2023 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37894418
12.
Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities.
Front Oncol
; 12: 889686, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35619925
13.
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Sci Rep
; 12(1): 8275, 2022 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35585158
14.
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Urol Oncol
; 40(1): 8.e11-8.e18, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34325986
15.
miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells.
Cancers (Basel)
; 13(5)2021 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33669024
16.
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
Biomedicines
; 9(6)2021 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34072926
17.
Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
Sci Rep
; 11(1): 14244, 2021 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34244564
18.
Antibody selection influences the detection of AR-V7 in primary prostate cancer.
Cancer Treat Res Commun
; 24: 100186, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619831
19.
Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53.
Urol Oncol
; 38(9): 736.e1-736.e10, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32674955
20.
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
Urol Oncol
; 36(8): 365.e15-365.e26, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29887238